Name of Journal: World Journal of Gastroenterology

Manuscript NO: 76864

Manuscript Type: REVIEW

Gut Microbiota Alteration and Modulation in HBV-related Fibrosis and Complications: molecular mechanisms and therapeutic inventions

Yao-Guang Li, Zu-Jiang Yu, Ang Li, Zhi-Gang Ren

Abstract

Hepatitis B virus (HBV) has posed a threat to public health, mainly resulting in liver damage. With long-term accumulation of extracellular matrix, patients with chronic hepatitis B are at high risk of developing into liver fibrosis and cirrhosis and even life-threatening hepatic carcinoma. The occurrence of complications such as spontaneous bacterial peritonitis and hepatic encephalopathy greatly increases disability and mortality. With deeper understanding of the bidirectional interaction between the liver and the gut (gut-liver axis), there is a growing consensus that the human health closely relates to the gut microbiota. Supported by animal and human studies, the gut microbiota alters as the HBV-related liver fibrosis initials and progresses, characterized as the decrease of the ratio between “good” and “potentially pathogenic” microbes. When the primary disease is controlled via antiviral treatment, the gut microbiota dysfunction tends to be improved. Conversely, the recovery of gut microbiota can promote the regression of liver fibrosis. Therapeutic strategies targeted on gut microbiota (rifaximin, probiotics, engineered probiotics and fecal microbiota transplantation) have been applied to animal models and patients, obtaining satisfactory results.

Key Words: Hepatitis B virus; Gut microbiota; Liver fibrosis; Liver cirrhosis; Hepatic encephalopathy; Fecal microbiota transplantation

**Core Tip:** Intimate connection between the gut microbiota alteration and HBV-related fibrosis and complications has been supported by animal and human studies. Researchers and clinicians are making effort to control and reverse fibrosis by rebuilding a healthy gut microbiota. We herein discuss the gut microbiota alteration in HBV-related fibrosis and therapies targeted on reconstruction of gut microbiota homeostasis.
INTRODUCTION

Hepatitis B virus (HBV) has brought about substantial global health problems, giving rise to approximately 1.5 million new infections in 2019 \[1\]. Balancing the pathogenic ability and immunity defense, some patients may experience chronic HBV infection, and even chronic hepatitis B (CHB). The different phrases are designed by the presence of hepatitis B e antigen (HBeAg), HBV DNA levels, alanine aminotransferase (ALT) values and liver inflammation, and CHB is mainly characterized by elevated ALT levels and moderate/severe liver diseases \[2\]. Chronic HBV infection tends to be asymptomatic initially, however, tissue repair against chronic inflammation may result in an immoderate accumulation of extracellular matrix (ECM), so CHB patients are at high risk of developing progressive fibrosis and life-threatening cirrhosis. Complications, such as portal hypertension, spontaneous bacterial peritonitis (SBP) \[3\] and hepatic encephalopathy (HE) \[4\], are different to prevent and address. With hepatic carcinoma (HCC) coming along stealthily \[5\], approximately 820,000 deaths were caused by HBV infection–related causes in 2019 \[1\].

The human intestine, as an organ directly connected with the outside world, is colonized by microbes progressively after birth \[6\]. The human gut microbiota is now considered to be composed of approximately $10^{14}$ bacteria \[7\], 200-300 fungal species \[8\] and abundant bacteriophages \[9\], and is increasingly seen as a significant superorganism \[10\]. Predominant strains in the adult intestine belong to Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria: Bacteroidetes and Firmicutes are the most dominant phyla and are mainly composed of gram-negative bacteria and gram-positive clostridia respectively \[11\]. The composition of the gut microbiota is influenced by age, race, nutrition, diet, immunity, disease and medication use, and has a strong interaction with the host \[12–14\]. The intimate association between gut microbiota homeostasis and multiple organ disease progression has been confirmed in the past decade, especially in some metabolic disorders \[15\], and intestinal and liver diseases \[16\].

The liver is closely connected with the gut via the gut-liver axis, defined as the bidirectional interaction between the liver and the gut via transport of bile acids,
immunoreactive substances, nutrients, etc. [17]. When impairment of intestinal barriers and disturbances of the gut microbiota occur, gut-derived microbe/antigen translocation may lead to invasion of the liver. The association between gut microbiota alterations and chronic liver diseases (CLDs) has received great attention.

This review will concentrate on gut microbiota alterations in HBV-related liver fibrosis and summarize the cutting edge of new therapeutic strategies. We will summarize and discuss (1) gut microbiota alteration in HBV-related liver fibrosis, (2) gut microbiota-related mechanisms of liver fibrosis, (3) gut microbiota dysfunction in liver fibrosis complications, and (4) gut microbiota-related treatment toward HBV-related fibrosis and complications.

**GUT MICROBIOTA ALTERATION IN HBV-RELATED LIVER FIBROSIS**

HBV-infected populations tend to obtain a gut microbiota that differs from that of healthy people (Table 1). Depending on host and viral factors, patients with HBV infection may experience different phrases [2]. In this part, gut microbiota alteration in the HBV persistence and different stages of HBV infection will be discussed.

**HBV persistence**

After the infection, HBV may be spontaneously cleared or cause chronic infection in different individuals: 95% of adult-acquired infections result in spontaneous clearance, while over 90% of newborn infections lead to chronic infections [18]. The same phenomenon has been observed in animal experiments, in which hepatitis B surface antigen (HBsAg) of immature mice remained positive [19]. The age-related difference in immune clearance of HBV is consistent with the stabilization time of the gut microbiota, and maturation appears to facilitate HBV clearance by diminishing the tolerance phenotype and stimulating the immunoreactive pathway [19, 20]. Similarly, if the gut microbiota was greatly imbalanced by antibiotics, the depletion can impair intestinal barrier function and weaken the ability of humoral and cellular immunity to clear HBV:
adult mice with a mature gut microbiota managed to clear HBV after 6 wk of infection, while they failed to do so after antibiotic use\textsuperscript{[19, 21]}.

**Acute HBV infection**

Due to the difficulty of studying acute HBV infection in humans, animal studies have been used: the ratio of *Firmicutes/Bacteroides* increased in the early stages of infection (Day 14) and decreased significantly over time (Day 49) in two mouse groups that were constructed with different plasmids\textsuperscript{[22]}.

**Chronic HBV infection and HBV-related liver fibrosis and cirrhosis**

Compositional changes have already occurred in the gut microbiota in early-stage CHB patients: in the Child-Pugh A and B groups, the abundance of 5 operational taxonomic units (OTUs) belonging to *Actinomyces, Clostridium sensu stricto*, unclassified *Lachnospiraceae* and *Megamonas* increased, while 27 OTUs decreased, which belong to *Alistipes, Acoscharobacter, Bacteroides, Butyririmonas, Clostridium IV*, etc.\textsuperscript{[23]}.

To further understand the gut microbiota dynamics in chronic HBV infection, there are also studies concentrating on the association with clinical indicators reflecting liver function and infection state. The gut microbiota of subjects from the Chronic HBV infection group with normal ALT (NALT) levels was rather similar to those from the healthy volunteers, while significantly different from those from the high ALT level group\textsuperscript{[24]}; however, in a recent study, the authors presented a slightly different perspective that the microbial diversity and abundance of *Lactobacillus, Clostridium*, and *Bifidobacterium* were lower in CHB-NALT patients than in healthy volunteers\textsuperscript{[25]}. *Streptococcus, Veillonella, Streptococcus* and *Haemophilus* showed high correlations with some serum metabolites, including aromatic amino acids (phenylalanine and tyrosine), which are assumed to play pathogenic roles the progression of CHB\textsuperscript{[23]}. The gut microbiota also varies according to viral load: HBV-infected individuals with a low viral load showed high diversity and carry a predominance of taxa associated with fatty acid and lipid metabolism\textsuperscript{[26]}.
As the disease progresses, the gut microbiota changes dynamically: the α diversity of asymptomatic HBV carriers slightly increased compared with that of healthy donors, while that of patients in the other three groups (CHB, liver cirrhosis, and acute-on-chronic liver failure (ACLF)) decreased with the severity of the disease [27]. The gut microbiota of patients with liver cirrhosis showed lower diversity and higher network complexity [38]. Veillonellaceae and Lachnospiraceae families were depleted in patients with liver cirrhosis compared with those in healthy volunteers, while Megamonas and Veillonella genera were depleted and enriched in patients, respectively [29]. Additionally, copy numbers of Enterobacteriaceae increased and lactic acid bacteria were depleted, with marked variation in the intestinal community of CHB patients [30]. The Bifidobacteria/Enterobacteriaceae ratio can be used for tracing the progression of liver disease [30]. With the magnitude of severity of liver disease (estimated as increasing liver Child-Pugh score), partial functional genes were correlated, such as those encoding aspartate-ammonia ligase, transaldolase, adenylosuccinate synthetase and IMP dehydrogenase [31]. According to the combined results of multiple studies, there is a well-acknowledged decrease in Firmicutes abundance and increase in Proteobacteria during the progression of HBV-related fibrosis.

**Hepatocellular carcinoma (HCC) and end-stage CHB**

Liver cirrhosis is a dangerous premalignant condition with an increasing incidence of genetic aberrations and an elevated risk of HCC [32, 33]. HCC patients tend to present a distempered gut microbiota and abnormal metabolites [34]. The butyrate-producing genera were depleted, while lipopolysaccharide (LPS)-producing genera were enriched in liver cirrhosis and HCC patients, and Clostridioides abundance was generally observed to be positively related to the tumor size of HCC [35]. In another study, Bacteroides, Lachnospiraceae incertae sedis, and Clostridium XIVa were enriched in HCC patients, and there was a consistency of positive correlation with the tumor burden [36]. By integrating the clinical characteristics and database analysis, serum bile acids may be the communication mediators between these three genera and the host transcriptome.
HCC can be secondary to a number of causes, including HBV, *Hepatitis C virus* (HCV) and so on. Compared with non-HBV non-HCV HCC, the abundance of *Prevotella* was much greater in HBV-related HCC group [34]. HBV-related HCC group had higher abundance of pathways related to DNA formation and function (including chaperones and folding catalysts, DNA replication proteins and chromosome), which supported that HBV can impair the normal function of DNA [34].

Additionally, dynamic alteration of gut microbiota is a valuable indicator to predict the prognosis of end-stage liver disease. The richness of *Enterococcus* was significantly higher in the HBV-related acute-on-chronic liver failure (ACLF) progression group, while a high abundance of *Faecalibacterium* was associated with regression (groups were divided according to the model for end-stage liver disease at discharge) [37]; a higher abundance of *E. coli* is consistent with an increasing level of LPS ligand in the circulation of patients with end-stage liver disease [38-40].

**GUT MICROBIOTA-RELATED MECHANISMS OF LIVER FIBROSIS**

Liver fibrosis is fibrous scar caused by excess accumulation of ECM [41]. It is driven by the chronic and persistent occurrence of parenchymal injury and the activation of the inflammatory response, followed by a continuous repair reaction and liver fibrogenesis [42]. For HBV infection, liver infringement comes from not only HBV but also gut-derived microbe/antigen translocation and abnormal metabolites.

There is a close connection between the gut and liver through known organic pipelines (bile duct and portal vein) [43], and whether there are detours needs further study. The liver produces and sends primary bile acids (BAs) and immunologic active materials (some antimicrobial peptides) through the biliary tract to assist in intestinal digestion and immunity. Conversely, the portal vein carries secondary BAs, nutrients, gastrointestinal metabolites from the gut to the liver, to provide nutrients and get detoxification and biotransformation [17, 44] (Figure 1a).

In a non-disease state, intestinal physical and chemical barriers effectively block pathogens or toxic substances and decrease bacterial colonization. The barriers mainly
include mucin proteins secreted by goblet cells, secretory IgA (sIgA) secreted by plasma cells in lymphoid follicles of the lamina propria and tight junctions between intestinal epithelial cells (IECs) \(^{[45]}\) (Fig. 1b). Disorders of these barriers can lead to increased intestinal permeability and translocation of microbial components or metabolites (LPS, microbial DNA) in CLD patients, allowing microbes and antigens to translocate into the portal vein \(^{[45]}\), and subsequently induce chronic or acute inflammatory responses of different tissues and organs \(^{[46]}\) (Figure 1c).

**Intestinal barrier impairment**

The gastrointestinal mucus layer is the first line of defense against microbes, and the mobility enables the layer to carry pathogens distally and reduce microbial colonization \(^{[47]}\). The experimental mouse models with liver cirrhosis [induced by bile-duct ligation (BDL) or tetrachloromethane (CCl\(_4\))] show a reduced thickness of the mucus layer, with loss of goblet cells \(^{[48]}\). These cirrhotic mice show pathological bacterial translocation, which has not been found in healthy or pre-hepatic portal-hypertensive mice \(^{[48]}\). sIgA is the predominant contributor to mucosal immunity, recognizing and eliminating bacterial protein antigens, and it also participates in barrier layer limitation of microbe/antigen translocation \(^{[49]}\). Patients with HBV-induced decompensated cirrhosis have increased sIgA content in blood and stool \(^{[50]}\), consistent with the increased bacterial migration. Simultaneously, intestinal tight junctions are weakened in patients with liver cirrhosis, and the expression of tight junction proteins is decreased \(^{[50, 51]}\). Zonulin, an effective physiological regulator of tight junctions, is one of the markers of intestinal permeability \(^{[52]}\). Serum zonulin content is significantly increased in HBV-related liver cirrhosis and HCC patients and the levels are correlated with the stages \(^{[53]}\).

**Gut-derived microbe/antigen translocation and metabolic dysbiosis**

The impairment of the intestinal barrier greatly reduces the efficiency of blocking microbe/antigen translocation. Gut-derived microbes or fragments and metabolites enter the venous system, travel through the portal vein to invade the liver. Diversity of
circulating bacteria in cirrhosis patients is consistent with the presence of dysbiosis [54]. Recent studies have also supported that the occurrence of intestinal bacterial overgrowth and bacterial translocation in cirrhosis using methods such as bacterial DNA sequencing [55] and fluorescence microscopy [21] and suggested that the mechanism is associated with antimicrobial host defense [56]. Simultaneously, LPS is one of the component of the outer membrane of Gram-negative bacteria, mainly from Enterobacteriaceae [57]. The dysbiosis of the gut microbiota in mice leads to endotoxemia, which may bring about Kupffer Cell (KC) IL-10 production and KC-mediated T cell suppression [57]. And endotoxemia is highly related to the severity in liver diseases and complications [58].

Additionally, abnormal composition of the gut microbiota results in metabolic disorders, among which the metabolism of BAs has aroused great concern [25]. The level of fecal total BAs decreased and the ratio of conjugated and primary BAs increased in CHB patients without liver cirrhosis, which may be the prelude of following changes [25]. And there is a trend that abundance of the bacteria genera responsible for BA metabolism is decreased in CHB patients with moderate/advanced fibrosis [59,60]. There is also a link between gut bacteria-controlled BA metabolism and liver antitumor immunosurveillance via natural killer T (NKT) cells [61].

**Immune-mediated fibrosis and regression**

Pattern recognition receptors (PRRs) are highly conserved host sensors that are able to recognize exogenous and endogenous antigens, including pathogen-associated molecular patterns (PAMPs) and host-derived damage-associated molecular patterns (DAMPs) [62]. PRRs are expressed by a plethora of immune cells, especially macrophages [63]. Macrophages could be at the center of innate immune regulation, linking microbe/antigen translocation and liver inflammation or fibrosis [64]. Recognition of PRRs sends the initial signal to active downstream adaptor proteins to undergo maturation and assemble transcription factors, such as nuclear factor (NF)-κB
The produced cytokines then recruit inflammatory cells, drive antimicrobial activities and promote myofibroblast formation [67].

Myofibroblasts, the collagen-producing cells, are not present in healthy livers [68]. In response to toxic liver injury, myofibroblasts are mainly transformed from activated hepatic stellate cells (HSCs) [69]. There are four different stages of HSCs, namely, quiescent, activated (equivalent to collagen type I-producing myofibroblasts), inactivated and senescent [41]. Under physiological conditions, quiescent HSCs stay in the space of Disse and function as the major vitamin A storage site [70]. Simulated by several cytokines (especially transforming growth factor (TGF)-β) [71], quiescent HSCs modulate phenotypes and transform into activated HSCs, and the activated HSCs migrate and secrete ECM to produce a fibrous scar [41]. After removing the initial driver, there is a decrease in the levels of pro-inflammatory cytokines (interleukin-6, interleukin-1β and tumor necrosis factor) and TGF-β, and a rapid decline of the counts of activated HSCs [41]. Activated HSCs can be transformed into inactivated or senescent cells, and stop producing type-I collagen fibers [72]. Later, when fiber degradation by matrix metalloproteinases overwhelms fiber formation, liver fibrosis can be controlled, regressed and even reversed [73].

In conclusion, increased microbe and endotoxin loads in the portal vein cause PRR activation on immune cells, especially on macrophages, which leads to the activation of quiescent HSCs into activated HSCs [44, 66]. Later, activated HSCs proliferate in response to various cytokines, secrete type-I collagen fiber and make liver fibrotic [41]. Upon cessation of underlying injury, myofibroblasts undergo inactivation or apoptosis, and fibrosis can be discontinued or reversed [41] (Figure 1d). This is the mechanism of effective treatment to control and regress liver fibrosis.

GUT MICROBIOTA DYSFUNCTION IN LIVER FIBROSIS COMPLICATIONS

As mentioned above, gut microbiota alterations may drive immune-related inflammation and fibrosis in the liver. Due to the accumulation of collagen fiber, liver stiffness is increased, bloodstream transport is blocked, healthy liver parenchyma is
replaced and liver biotransformation and detoxification abilities are weakened. As the disease progresses into the decompensation stage, patients may experience deadly complications, such as portal hypertension, spontaneous bacterial peritonitis (SBP) and hepatic encephalopathy (HE). The relationship among gut microbiota alteration, liver fibrosis and portal hypertension is similar to the question of the chicken and the egg, as they drive and affect each other. Compared with compensated cirrhosis, gut microbiota composition is characterized by an increase in the abundance of potentially pathogenic bacteria in the decompensation stage, especially Alcaligenaceae, Porphyromonadaceae, Veillonellaceae and Enterobacteriaceae.

**Spontaneous bacterial peritonitis (SBP)**

SBP refers to the infection of ascites without an apparent intra-abdominal focus. It is a severe infection and is often fatal in patients with cirrhosis and ascites. The pathogen of SBP in liver cirrhosis patients is mainly from the intestinal tract.

More than two decades ago, DNA fragments of 30 bacterial isolated from ascites, mesenteric lymph nodes, portal blood, and ileal flora were compared. The same bacterial strain was simultaneously isolated in ascites and in mesenteric lymph nodes and/or the ileum in 7/8 (87%) instances. Intraperitoneal LPS increased TLR4 (Toll-like receptor 4, the canonical PRR for LPS) expression and amplified portal hypertension in rat liver fibrosis.

**Hepatic encephalopathy (HE)**

HE is a fatal central nervous system complication caused by acute and chronic hepatitis or decompensated cirrhosis, which is considered consciousness disturbance after ammonia-related cerebral edema. HE patients tend to have a poor prognosis and high mortality and recurrence rates, with greatly increasing economic and nursing burdens.

Currently, there is an increasing consensus that the gut microbiota and gastrointestinal metabolites play an important role in the initiation and progress of HE.
On the basis of the gut-liver axis mentioned above, researchers proposed the concept of the gut-brain-liver axis to describe the role of the gut microbiota [84]. Cognitive dysfunction in cirrhosis is related to a decrease in the abundance of autochthonous families and an increase in Alcaligenaceae and Porphyromonadaceae [85, 86].

On the one hand, gut microbiota alteration in the decompensation stage is consistent with the accumulation of microbe-derived products, including ammonia, mercaptans, benzodiazepine-like substances, and indoles [76]. These products can pass the blood-brain barrier and alter astrocyte function, resulting in osmotic or oxidative stress, mitochondrial dysfunction, neurotransmission disorder, etc. [81]. On the other hand, neurotransmitters produced by the microbiota, including serotonin, dopamine, and aminobutyric acid, can act on specific receptors of exogenous primary afferent neuron cells, or cross the blood-brain barrier to act as active neurotransmitters [87]. The complex network among the enteric nervous system, the autonomic nervous system and the neuroendocrine and neuroimmunity systems of the central nervous system has a mutual impact on the gut microbiota, and the up-down or down-up regulation mechanisms need further exploration [84].

GUT MICROBIOTA-RELATED TREATMENT TOWARD HBV-RELATED FIBROSIS AND COMPLICATIONS

Based on the fibrosis regression theory mentioned above, removing the cause is the key to controlling and reversing liver fibrosis (Table 2, Table 3). For more than a decade, antiviral therapy has been recognized as an effective method to prevent, control and even reverse fibrosis and cirrhosis [88]. Rifaximin reduces the virulence of the overgrown gut microbiota [89]. With further understanding of the connection between the gut microbiota and HBV-related fibrosis, scientists have suggested that host health depends on the balance of the composition of the entire microbial community rather than one or a few dominant organisms [90]. New therapeutic strategies for HBV-related fibrosis, cirrhosis and complications have been broadened to regulate the gut microbiota.
through probiotic supplementation and microbiota transplantation from healthy donors.

**Gut microbiota stabilization with antiviral treatment (AVT)**

At present, the main endpoint of all current treatment strategies is to maintain long-term suppression of HBV replication [2]. Two main options are nucleoside analogs (NAs) and interferon alpha [91]. NAs with a high barrier to HBV resistance, including entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), are believed to be favorably safe and long-acting [92]. AVT exerts a positive influence on survival rate and quality of life by preventing disease progression, reversing and degrading fibrosis and cirrhosis [93,94], and even reducing HCC incidence and mortality in CHB patients [95].

ETV therapy reverses gut microbiota dysbiosis induced by HBV infection in a mouse model [96]. And in a controlled cross-sectional and longitudinal real-world study, the species abundance of the gut microbiota increased markedly after ETV treatment [97]. After 8 wk of ETV treatment, the abundance of *Clostridium sensu stricto 1*, *Erysipelotrichaceae UCG-007* and *Intestinibacter* increased significantly, and that of *Streptococcus*, *Atopobium* and *Murdochella* was markedly reduced [97]. Although the addition of *Clostridium butyricum* (CB) to ETV failed to improve the serum biochemical, immunologic and virologic variables, addition of CB affected the gut microbiota in CHB patients treated with ETV [98]. While there is a lack of dynamic and synergetic studies on liver fibrosis outcomes and gut microbiota alterations during AVT, collaborative microbes contributing the most to antiviral-intervened HBV-related fibrosis cannot be pinpointed definitively.

**Rifaximin**

Rifaximin is a rifamycin-based nonsystemic antibiotic with low gastrointestinal absorption and good antibacterial activity [89,99]. The gastrointestinal tract is the main
therapeutic target of rifaximin, and it has been widely used in controlling HE with infrequent side effects and a favorable long-term safety profile [100, 101].

Current ideas suggest that rifaximin may have positive implications for liver cirrhosis and complications by acting on the gut microbiota. However, according to a randomized trial, there seems to be a minor impact on the composition of the gut microbiota [102]. Enrolled patients with cirrhosis and ascites were divided into two groups to receive rifaximin or placebo for 4 wk. Rifaximin decreased gut bacterial abundance, while no effect on particular species was observed; blood bacterial richness was decreased and the difference in Pseudomonadales abundance was relatively obvious [102]. And there was no difference in circulating markers of inflammation between the two groups [102]. Two additional studies also supported that rifaximin has little influence on gut microbiota abundance [103], but the metabolite levels altered: after rifaximin application, endotoxemia was relieved, and serum saturated and unsaturated fatty acid levels were increased significantly [104]. The former conclusion agreed with a study on experimental mice [105]. Therefore, rather than having a bactericidal effect, rifaximin seems to have direct effects on bacterial function and virulence [89].

Probiotics and synthetic probiotics
Probiotics are living nonpathogenic microorganisms, and treatment doses (at least 10^6 viable CFU/g) may help temper the gut microbiota [106]. Lactobacillus and Bifidobacterium genera are widely reported as clinically available probiotics [107]. In recent studies, probiotics have been broadly used to regulate the gut microbiota for further positive influences on primary diseases, such as gastrointestinal dysfunctions [108, 109], metabolic diseases [110, 111] and psychoneurotic disorders [112, 113].

The role of probiotics in complications of HBV-related fibrosis and cirrhosis has been validated, especially for HE. Probiotics can drive the gut microbiota, triggering emotional brain signatures [114]. For minimal hepatic encephalopathy (MHE), probiotic therapy (Lactobacillus acidophilus) can improve blood ammonia and psychometric tests and reduce the risk of overt encephalopathy deterioration [115]. Further studies
confirmed that patients’ cognition, venous ammonia level and intestinal mucosal barrier function were significantly improved after 3 mo of probiotic use (Clostridium butyricum combined with Bifidobacterium infantis), and the predominant bacteria (Clostridium cluster I and Bifidobacterium) were obviously enriched in the probiotic-treated group, while Enterococcus and Enterobacteriaceae were depleted. The combination of probiotics and lactulose is effective for the secondary prophylaxis of HE patients with cirrhosis. Simultaneously, probiotics may work by promoting the growth of beneficial microbes and preventing PAMP-mediated liver inflammation and the anti-proliferative, anti-angiogenic, and anti-metastatic effects of the antioxidant can block the progress of HCC.

Additionally, rapid progress in synthetic biology has brought more options, which makes engineered live biotherapeutics an available and promising strategy. More than one decade ago, the genetically engineered ammonia-hyperconsuming strain NCIMB8826 was verified to exhibit a beneficial effect at a lower dose than its wild-type counterpart. In recent years, more engineered bacteria have been constructed to accelerate ammonia metabolism, reduce blood ammonia concentration and reduce HE incidence. One team from Synlogic Inc. engineered oral probiotic Escherichia coli Nissle 1917 (EcN) to create strain SYNBI020. SYNBI020 is able to convert NH3 to L-arginine in vivo and reduce hyperammonemia in two mouse models (ornithine transcarbamylase-deficient spfash mice and thioacetamide-induced liver injury mice). Satisfyingly, it showed metabolic activity and good tolerance in a phase 1 clinical study of 52 healthy adult volunteers. Later, another group modified EcN to consume and convert ammonia to arginine, which was further modified to additionally synthesize butyrate. Both of these studies showed that engineered probiotics have positive therapeutic significance for hyperammonemia and underlying potential for HE prevention. However, these strains have not progressed to clinical studies in hyperammonemia patients, and the clinical effects need further study.

Fecal microbiota transplantation (FMT)
FMT is an emerging treatment method that transfers the gut microbiota from a healthy donor to a patient\textsuperscript{[123]}. Due to its ability to directly reshape or rebuild the recipient’s gut microbial communities, FMT is one of the most promising therapies balancing and stabilizing the gut microbiota\textsuperscript{[76]}, and it has been applied to research-based treatment in animal models of a variety of diseases\textsuperscript{[124, 125]} and to study the mechanisms\textsuperscript{[126, 127]}. In recent years, FMT has been expanded to clinical treatment for human disease as a noninvasive strategy for conditions including recurrent \textit{Clostridium difficile} infection\textsuperscript{[128]}, inflammatory bowel disease\textsuperscript{[129]}, severe obesity and metabolic syndrome\textsuperscript{[130]}. Regarding the mechanism, the gut microbiota structure can be improved by FMT, and a clinical trial employing autologous FMT supported this point\textsuperscript{[134]}.

Clinical trials have also aimed to determine whether CHB patients can benefit from FMT therapy. In a pilot study carried out in China, FMT showed the potential to induce HBeAg clearance in HBeAg-positive CHB patients after long-term AVT: there was a significant HBeAg level decline in the FMT group (FMT combined with AVT), while no decline in the control group (AVT only) was found\textsuperscript{[132]}. The results were consistent with a nonrandomized controlled clinical trial carried out in India: after 1 year of FMT therapy for 6 terms, the FMT group (FMT + AVT) seemed to show potential effectiveness and safety compared with those of the AVT group (AVT only)\textsuperscript{[133]}. Some researchers have also hypothesized that FMT of some potential beneficial bacteria can change the occurrence of disease, and HBV carriers might be the most suitable donors for slightly higher microbiota abundance\textsuperscript{[27]}. However, due to the limitations of a small number of participants and a lack of randomized clinical trials, further well-designed clinical trials are needed to confirm the initial assumptions and promote clinical practicability.

Studies on FMT for HE animal models or patients show satisfactory results. In animal experiments, neuroinflammation alleviation was found in cirrhosis model mice receiving FMT\textsuperscript{[134]}. In a randomized clinical trial, FMT from rationally selected donors helped reduce and improve hospitalizations and improve cognition and dysbiosis for cirrhosis with recurrent HE\textsuperscript{[135]}. Later, the same team verified the safety of FMT
capsules through a phase 1, randomized and placebo-controlled clinical trial \[136\]. In addition to integral inoculation, selective inoculation of specific strains also plays an ameliorating role. Transplanting low-urease altered Schaedler flora to mice prepared with a depleted microbiota led to durable reduction in fecal urease activity and ammonia production \[137\]. The symbiotic pair of \textit{Lactobacillus reuteri} JBD400 and \textit{Streptococcus rubneri} JBD420 cooperatively improved transplantation efficiency \(2.3 \times 10^3\) times more than that of sole transplantation and significantly lowered blood ammonia levels \[138\].

**CONCLUSION**

Consequently, gut microbiota alteration has been observed to be related to HBV-related fibrosis initiation and progression, and it is a promising therapeutic target. According to current studies, HBV persistence and clearance show consistency with the maturity and health of the gut microbiota \[19,21\]. With an increase of Child-Pugh scores and the model for end-stage liver disease, the gut microbiota is characterized by a decrease in the ratio of "good" to "potentially pathogenic" bacteria, and species diversity tends to decrease \[139,140\]. However, it is difficult to clarify which is the initiating factor between gut microbiota alteration and HBV-related fibrosis progression. Existing studies tend to be descriptive and lack HBV-specific exploration. Gut microbiota-related mechanisms are based on the gut-liver axis and immune-mediated response, briefly including intestinal barrier impairment, PRR activation, cytokine production, HSC activation and transformation, and fiber secretion and formation \[41\]. When the driver is removed, activated HSCs are inhibited or become apoptotic, and fiber scars are degraded, resulting in fibrosis regression \[41\].

Beyond theory, quite a few studies have begun examining therapeutic inventions. AVT can effectively control or even reverse HBV-related liver fibrosis, during which the gut microbiota gradually returns to homeostasis \[96,97\]. Rifaximin may decrease the virulence of the overgrown gut microbiota \[89\]. Probiotics and FMT are the most popular gut microbiota targeted therapies, and they are moving from the laboratory to the clinic.
In addition, synthetic probiotics and selective microbiota transplantation may make these therapies more precise, and bring fewer side effects.

However, current studies do have limitations. There is a lack of in-depth research on the specific molecular mechanisms of the gut microbiota. Further clinical studies are needed to determine its effectiveness in patients with HBV-induced liver cirrhosis in the real world [141]. We must also admit that age, host location, dietary habits have a great impact on the gut microbiota, which leads to the lack of consistency and comparability of the alterations in gut microbiota in different studies. Therefore, diagnosis potential of microbial markers should be considered the factors mentioned above. We are looking forward to more powerful studies to strengthen the theoretical foundation and promote clinical application.
<table>
<thead>
<tr>
<th>#</th>
<th>Source Address</th>
<th>Title</th>
<th>Excluded Matches</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>new.esp.org</td>
<td></td>
<td>43 words — 1%</td>
</tr>
<tr>
<td>4</td>
<td><a href="http://www.esp.org">www.esp.org</a></td>
<td></td>
<td>32 words — 1%</td>
</tr>
<tr>
<td>5</td>
<td>aasldpubs.onlinelibrary.wiley.com</td>
<td></td>
<td>31 words — 1%</td>
</tr>
</tbody>
</table>